Diabetes negatively affects cortical and striatal GABAergic neurons: An effect that is partially counteracted by exendin-4

Bioscience Reports

Volumn 36, Issue 6, 2016, Pages

  Larsson, Martin ^a   Lietzau, Grazyna ^a,b   Nathanson, David ^a   Östenson, Claes Göran ^a   Mallard, Carina ^c   Johansson, Maria E ^c   Nyström, Thomas ^a   Patrone, Cesare ^a   Darsalia, Vladimer ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Diabetes; Exendin 4; Glucagon like peptide 1 receptor (GLP 1R); Interneurons; Neurological complications; aminobutyric acid (GABA)

Indexed keywords

CALBINDIN; CALRETININ; CYTOKINE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUTAMATE DECARBOXYLASE 67; PARVALBUMIN; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 1; PEPTIDE; VENOM;

ADULT; AGE; AGED; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CELL DENSITY; CELL VOLUME; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; GABAERGIC SYSTEM; GOTO KAKIZAKI RAT; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERNEURON; MICROSCOPY; MIDDLE AGED; NEOCORTEX; NEUROLOGICAL COMPLICATION; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; QUANTITATIVE ANALYSIS; RAT; WISTAR RAT; YOUNG ADULT; ANIMAL; DIABETES MELLITUS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PHYSIOLOGY;

ANIMALS; CALBINDIN 2; CALBINDINS; CORPUS STRIATUM; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; GABAERGIC NEURONS; GAMMA-AMINOBUTYRIC ACID; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUTAMATE DECARBOXYLASE; NEOCORTEX; PARVALBUMINS; PEPTIDES; RATS; RATS, WISTAR; VENOMS;

EID: 85002878399     PISSN: 01448463     EISSN: 15734935     Source Type: Journal    
DOI: 10.1042/BSR20160437     Document Type: Article

References (72)

1. IDF Diabetes Atlas (2015) [cited 2016 2016-03-21]. 7th ed: Available from: www.diabetesatlas.org
2. Organization, W.H. (2015) Diabetes fact sheet [cited 2016 2016-03-21]. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/
3. Forbes, J.M., Cooper, M.E. (2013) Mechanisms of diabetic complications. Physiol. Rev. 93, 137-188 CrossRef
4. Papatheodorou, K., Banach, M., Edmonds, M., Papanas, N. and Papazoglou, D. (2015) Complications of diabetes. J. Diabetes Res. 2015, 5 CrossRef
5. Cashman, C.R. and Hoke, A. (2015) Mechanisms of distal axonal degeneration in peripheral neuropathies. Neurosci. Lett. 596, 33-50 CrossRef
6. Peters, S.A.E., Huxley, R.R. and Woodward, M. (2014) Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539 strokes. Lancet 383, 1973-1980 CrossRef
7. Norhammar, A., Bodegard, J., Nystrom, T., Thuresson, M., Eriksson, J.W. and Nathanson, D. (2016) Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013. Diabetologia 59, 1692-1701 CrossRef
8. Pulsinelli, W.A., Levy, D.E., Sigsbee, B., Scherer, P. and Plum, F. (1983) Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. Am. J. Med. 74, 540-544 CrossRef
9. Kodl, C.T. and Seaquist, E.R. (2008) Cognitive dysfunction and diabetes mellitus. Endocr. Rev. 29, 494-511 CrossRef
10. Yates, K.F., Sweat, V., Yau, P.L., Turchiano, M.M. and Convit, A. (2012) Impact of metabolic syndrome on cognition and brain: a selected review of the literature. Arterioscler. Thromb. Vasc. Biol. 32, 2060-2067 CrossRef
11. Cukierman, T., Gerstein, H.C. and Williamson, J.D. (2005) Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. Diabetologia 48, 2460-2469 CrossRef
12. McCrimmon, R.J., Ryan, C.M. and Frier, B.M. (2012) Diabetes and cognitive dysfunction. Lancet 379, 2291-2299 CrossRef
13. Biessels, G.J. and Reagan, L.P. (2015) Hippocampal insulin resistance and cognitive dysfunction. Nat. Rev. Neurosci. 16, 660-671 CrossRef
14. Kalaria, R.N. (2009) Neurodegenerative disease: diabetes, microvascular pathology and Alzheimer disease. Nat. Rev. Neurol. 5, 305-306 CrossRef
15. Yusuf, A.J., Onyemelukwe, G., Amedu, M.A. and Olarinoye-Akorede, S. (2014) Cerebral atrophy and dementia in type 2 diabetes mellitus: report of two cases and review of literature. Niger. Postgrad. Med. J. 21, 81-85
16. Biessels, G.J. and Reijmer, Y.D. (2014) Brain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI? Diabetes 63, 2244-2252 CrossRef
17. Moroz, N., Tong, M., Longato, L., Xu, H. and de la Monte, S.M. (2008) Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J. Alzheimers Dis. 15, 29-44
18. Bhat, N.R. and Thirumangalakudi, L. (2013) Increased tau phosphorylation and impaired brain insulin/IGF signaling in mice fed a high fat/high cholesterol diet. J. Alzheimers Dis. 36, 781-789
19. Li, X.H., Xin, X., Wang, Y., Wu, J.Z., Jin, Z.D., Ma, L.N., Nie, C.J., Xiao, X., Hu, Y. and Jin, M.W. (2013) Pentamethylquercetin protects against diabetes-related cognitive deficits in diabetic Goto-Kakizaki rats. J. Alzheimers Dis. 34, 755-767
20. Cereda, E., Barichella, M., Cassani, E., Caccialanza, R. and Pezzoli, G. (2012) Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology 78, 1507-1511 CrossRef
21. McQuail, J.A., Frazier, C.J. and Bizon, J.L. (2015) Molecular aspects of age-related cognitive decline: the role of GABA signaling. Trends Mol. Med. 21, 450-460 CrossRef
22. Kann, O. (2015) The interneuron energy hypothesis: implications for brain disease. Neurobiol. Dis. 90, 75-85 CrossRef
23. Yi, S.S. (2013) Time-dependent changes of calbindin D-28K and parvalbumin immunoreactivity in the hippocampus of rats with streptozotocin-induced type 1 diabetes. J. Vet. Sci. 14, 373-380 CrossRef
24. Lietzau, G., Nystrom, T., Ostenson, C.G., Darsalia, V. and Patrone, C. (2016) Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4. Oncotarget 7, 5865-5876
25. Lovett-Barron, M. and Losonczy, A. (2014) Behavioral consequences of GABAergic neuronal diversity. Curr. Opin. Neurobiol. 26, 27-33 CrossRef
26. Wilson, C.J. (2007) GABAergic inhibition in the neostriatum. Prog. Brain Res. 160, 91-110 CrossRef
27. Druga, R. (2009) Neocortical inhibitory system. Folia Biol. (Praha). 55, 201-217
28. Castillo-Gomez, E., Coviello, S., Perez-Rando, M., Curto, Y., Carceller, H., Salvador, A. and Nacher, J. (2015) Streptozotocin diabetic mice display depressive-like behavior and alterations in the structure, neurotransmission and plasticity of medial prefrontal cortex interneurons. Brain Res. Bull. 116, 45-56 CrossRef
29. Drucker, D.J. and Nauck, M.A. (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696-1705 CrossRef
30. Heppner, K.M. and Perez-Tilve, D. (2015) GLP-1 based therapeutics: simultaneously combating T2DM and obesity. Front. Neurosci. 9, 92 CrossRef
31. Kastin, A.J. and Akerstrom, V. (2003) Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 27, 313-318 CrossRef
32. Darsalia, V., Larsson, M., Nathanson, D., Klein, T., Nystrom, T. and Patrone, C. (2015) Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke. J. Cereb. Blood Flow Metab. 35, 718-723 CrossRef
33. Holscher, C. (2014) Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 221, T31-T41 CrossRef
34. Patrone, C., Eriksson, O. and Lindholm, D. (2014) Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes Endocrinol 2, 256-262 CrossRef
35. Korol, S.V., Jin, Z., Babateen, O. and Birnir, B. (2015) GLP-1 and exendin-4 transiently enhance GABAA receptor-mediated synaptic and tonic currents in rat hippocampal CA3 pyramidal neurons. Diabetes 64, 79-89 CrossRef
36. Goto, Y., Kakizaki, M. and Masaki, N. (1976) Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J. Exp. Med. 119, 85-90 CrossRef
37. Ostenson, C.G. and Efendic, S. (2007) Islet gene expression and function in type 2 diabetes; studies in the Goto-Kakizaki rat and humans. Diabetes Obes. Metab. 9 (Suppl 2), 180-186 CrossRef
38. Murakawa, Y., Zhang, W., Pierson, C.R., Brismar, T., Ostenson, C.G., Efendic, S. and Sima, A.A. (2002) Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy. Diabetes Metab. Res. Rev. 18, 473-483 CrossRef
39. Hussain, S., Mansouri, S., Sjoholm, A., Patrone, C. and Darsalia, V. (2014) Evidence for cortical neuronal loss in male type 2 diabetic Goto-Kakizaki rats. J. Alzheimers Dis. 41, 551-560
40. Gundersen, H.J., Bendtsen, T.F., Korbo, L., Marcussen, N., Moller, A., Nielsen, K., Nyengaard, J.R., Pakkenberg, B., Sørensen, F.B., Vesterby, A. et al. (1988) Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 96, 379-394 CrossRef
41. Akash, M.S., Rehman, K., Sun, H. and Chen, S. (2013) Interleukin-1 receptor antagonist improves normoglycemia and insulin sensitivity in diabetic Goto-Kakizaki-rats. Eur. J. Pharmacol. 701, 87-95 CrossRef
42. Xue, B., Sukumaran, S., Nie, J., Jusko, W.J., Dubois, D.C. and Almon, R.R. (2011) Adipose tissue deficiency and chronic inflammation in diabetic Goto-Kakizaki rats. PLoS One 6, e17386 CrossRef
43. De Felice, F.G. and Ferreira, S.T. (2014) Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63, 2262-2272 CrossRef
44. Gault, V.A., Lennox, R. and Flatt, P.R. (2015) Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes Obes. Metab. 17, 401-413 CrossRef
45. Greenwood, C.E. and Winocur, G. (2005) High-fat diets, insulin resistance and declining cognitive function. Neurobiol. Aging 26 (Suppl 1), 42-45 CrossRef
46. Stranahan, A.M., Norman, E.D., Lee, K., Cutler, R.G., Telljohann, R.S., Egan, J.M. and Mattson, M.P. (2008) Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 18, 1085-1088 CrossRef
47. Sonnen, J.A., Larson, E.B., Brickell, K., Crane, P.K., Woltjer, R., Montine, T.J. and Craft, S. (2009) Different patterns of cerebral injury in dementia with or without diabetes. Arch. Neurol. 66, 315-322 CrossRef
48. Kann, O., Papageorgiou, I.E. and Draguhn, A. (2014) Highly energized inhibitory interneurons are a central element for information processing in cortical networks. J. Cereb. Blood Flow Metab. 34, 1270-1282 CrossRef
49. Markram, H., Toledo-Rodriguez, M., Wang, Y., Gupta, A., Silberberg, G. and Wu, C. (2004) Interneurons of the neocortical inhibitory system. Nat. Rev. Neurosci. 5, 793-807 CrossRef
50. Palovcik, R.A., Phillips, M.I., Kappy, M.S. and Raizada, M.K. (1984) Insulin inhibits pyramidal neurons in hippocampal slices. Brain Res 309, 187-191 CrossRef
51. Donzanti, B.A. and Ung, A.K. (1990) Alterations in neurotransmitter amino acid content in the aging rat striatum are subregion dependent. Neurobiol. Aging 11, 159-162 CrossRef
52. Ullberg, T., Zia, E., Petersson, J. and Norrving, B. (2015) Changes in functional outcome over the first year after stroke: an observational study from the Swedish stroke register. Stroke 46, 389-394 CrossRef
53. Heizmann, C.W. and Braun, K. (1992) Changes in Ca(2+)-binding proteins in human neurodegenerative disorders. Trends Neurosci. 15, 259-264 CrossRef
54. Blatow, M., Rozov, A., Katona, I., Hormuzdi, S.G., Meyer, A.H., Whittington, M.A., Caputi, A. and Monyer, H. (2003) A novel network of multipolar bursting interneurons generates theta frequency oscillations in neocortex. Neuron 38, 805-817 CrossRef
55. Bennett, B.D. and Bolam, J.P. (1993) Two populations of calbindin D28k-immunoreactive neurones in the striatum of the rat. Brain Res. 610, 305-310 CrossRef
56. Gerfen, C.R., Baimbridge, K.G. and Miller, J.J. (1985) The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. Proc. Natl. Acad. Sci. U.S.A. 82, 8780-8784 CrossRef
57. Iacopino, A.M. and Christakos, S. (1990) Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc. Natl. Acad. Sci. U.S.A. 87, 4078-4082 CrossRef
58. Ahmadian, S.S., Rezvanian, A., Peterson, M., Weintraub, S., Bigio, E.H., Mesulam, M.M. and Geula, C. (2015) Loss of calbindin-D28K is associated with the full range of tangle pathology within basal forebrain cholinergic neurons in Alzheimer's disease. Neurobiol. Aging 36, 3163-3170 CrossRef
59. Riascos, D., Nicholas, A., Samaeekia, R., Yukhananov, R., Mesulam, M.M., Bigio, E.H., Weintraub, S., Guo, L. and Geula, C. (2014) Alterations of Ca(2)(+)-responsive proteins within cholinergic neurons in aging and Alzheimer's disease. Neurobiol. Aging 35, 1325-1333 CrossRef
60. Kook, S.Y., Jeong, H., Kang, M.J., Park, R., Shin, H.J., Han, S.H., Son, S.M., Song, H., Baik, S.H., Moon, M. et al. (2014) Crucial role of calbindin-D28k in the pathogenesis of Alzheimer's disease mouse model. Cell Death Differ 21, 1575-1587 CrossRef
61. Lloyd, A.C. (2013) The regulation of cell size. Cell 154, 1194-1205 CrossRef
62. Moon, J.I. and Birren, S.J. (2008) Target-dependent inhibition of sympathetic neuron growth via modulation of a BMP signaling pathway. Dev. Biol. 315, 404-417 CrossRef
63. Koos, T. and Tepper, J.M. (1999) Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat. Neurosci. 2, 467-472 CrossRef
64. Kim, K.K., Adelstein, R.S. and Kawamoto, S. (2009) Identification of neuronal nuclei (NeuN) as Fox-3, a new member of the Fox-1 gene family of splicing factors. J. Biol. Chem. 284, 31052-31061 CrossRef
65. Rampersaud, N., Harkavyi, A., Giordano, G., Lever, R., Whitton, J. and Whitton, P.S. (2012) Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions. Neuropeptides 46, 183-193 CrossRef
66. Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H. and Wikström, L. (2008) Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 86, 326-338 CrossRef
67. Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A.E., Biggs, C.S. and Whitton, P.S. (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflammation 5, 19 CrossRef
68. Martin, B., Golden, E., Carlson, O.D., Pistell, P., Zhou, J., Kim, W., Frank, B.P., Thomas, S., Chadwick, W.A., Greig, N.H. et al. (2009) Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 58, 318-328 CrossRef
69. Darsalia, V., Nathanson, D., Nystrom, T., Klein, T., Sjoholm, A. and Patrone, C. (2014) GLP-1R activation for the treatment of stroke: updating and future perspectives. Rev. Endocr. Metab. Disord. 15, 233-242 CrossRef
70. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A. et al. (2013) Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 123, 2730-2736 CrossRef
71. Yenari, M.A., Minami, M., Sun, G.H., Meier, T.J., Kunis, D.M., McLaughlin, J.R., Ho, D.Y., Sapolsky, R.M. and Steinberg, G.K. (2001) Calbindin d28k overexpression protects striatal neurons from transient focal cerebral ischemia. Stroke 32, 1028-1035 CrossRef
72. Ehses, J.A., Lacraz, G., Giroix, M.H., Schmidlin, F., Coulaud, J., Kassis, N., Irminger, J.C., Kergoat, M., Portha, B., Homo-Delarche, F. and Donath, M.Y. (2009) IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc. Natl. Acad. Sci. U.S.A. 106, 13998-14003 CrossRef